Adelaide

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Amyloidosis2 trials
• Metastatic breast cancer2 trials

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Recruiting2 trials

Lead sponsor

• Alnylam Pharmaceuticals3 trials
• Olema Pharmaceuticals, Inc.2 trials

Running trials

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

  NCT06393712· Phase 2· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• Metastatic breast cancer1 recruiting